Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension

Posted in Biotech by Medtech[y] Staff

February 07, 2020 • 2 min read

Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, announced that Kevin Peters, M.D., Aerpio’s Chief Scientific Officer, pre...

Andreessen Horowitz Launches Third Bio Fund

Posted in Biotech by Medtech[y] Staff

February 05, 2020 • 2 min read

Well known venture capital firm, Andreessen Horowitz, announced they have launched their third bio fund, called BioFund III, years after saying they would never "do bio" as the firm's primary focus concentrates on investments ...